GlaxoSmithKline Pipeline Analysis: Robust Or Going Bust?

GlaxoSmithKline (NYSE:GSK) is a British, world-leading research-based biopharmaceutical and healthcare company committed to improving the quality of human life by enabling people to do more, feel better, and live longer, according to the company website. Analysts have noted that GSK revenues have declined over recent years as patents expire, but have conceded that it has a robust pipeline (Strong Bio defines a robust pipeline as a pipeline that requires a search engine on its website). However, its 2017 quarter-one report indicates growth of sales across all three businesses: Pharmaceuticals +17% AER, +4% CER; Vaccines +31% AER, +16% CER, and Consumer Healthcare +16% AER, +2% CER. Concurrent with this, one analyst, Exane BNP Paribas, has changed its rating from underperform to neutral in April 2017. As this turnaround (and Strong Bio likes to cover turnaround stories) may be in play as picked by some analysts, now is a good time to assess its future prospects to see if entering at the approximate current 4.85% dividend is likely to be cut or improve. The company expects the dividend to remain constant for 2017.

READ FULL ARTICLE HERE